Safety, Tolerance, and Efficacy of Posaconazole Therapy in Patients with Nonmeningeal Disseminated or Chronic Pulmonary Coccidioidomycosis | Zendy

Antonio Catanzaro | Zendy; Gretchen A. Cloud | Zendy; David A. Stevens | Zendy; Barrett's Esophagus Levine | Zendy; Pamela Williams | Zendy; R. H. Johnson | Zendy; Adrián Rendón | Zendy; Laurence F. Mirels | Zendy; J E Lutz | Zendy; M. Holloway | Zendy; J N Galgiani | Zendy

Open Access

Safety, Tolerance, and Efficacy of Posaconazole Therapy in Patients with Nonmeningeal Disseminated or Chronic Pulmonary Coccidioidomycosis

Author(s) -

Antonio Catanzaro,

Gretchen A. Cloud,

David A. Stevens,

Barrett's Esophagus Levine,

Pamela Williams,

R. H. Johnson,

Adrián Rendón,

Laurence F. Mirels,

J E Lutz,

M. Holloway,

J N Galgiani

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/519937

Subject(s) - medicine , posaconazole , intensive care medicine , antifungal , dermatology , itraconazole

Coccidioidomycosis can be difficult to treat with available therapies, particularly in patients with progressive or disseminated disease. Posaconazole is a new azole antifungal with potent activity against Coccidioides species, the causative agent of coccidioidomycosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research